Late Cytomegalovirus Infections After Allogeneic Hematopoietic Cell Transplant
American Journal of Hematology · 2026
DOI: 10.1002/ajh.70347 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, 2026. Verfasst von George L Chen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Graft versus host disease (GVHD) prophylaxis with posttransplant cyclophosphamide (ptCY) and cytomegalovirus (CMV) prophylaxis with letermovir have changed the clinical epidemiology of CMV infection. We studied the incidence, risk factors for, and outcomes of CMV infection after Day + 90 of allogeneic hematopoietic cell transplant (alloHCT). The patient cohort consisted of 2106 alloHCT patients treated from 2015 to 2022 with a single alloHCT. Fifty‐seven percent of patients received ptCY. Forty‐three percent of patients received letermovir. We performed landmark analysis of the cumulative incidence of CMV‐emia with the competing risk of death from Day + 0 to +360 in 90‐day intervals. Regression analyses of baseline and time‐dependent covariates for CMV‐emia and survival were performed for each interval. The cumulative incidence of CMV‐emia (≥ 500 IU CMV DNA/mL) was associated with donor/recipient CMV serostatus. In the highest risk CMV serostatus donor negative and recipient positive (D−R+) group, the cumulative incidence was 24.3 (95% confidence interval [CI] 21.3–27.3), 9 (95% CI: 6.9–11.1), 5 (95% CI: 3.3–6.7), and 2.1 (95% CI: 0.9–3.3) from Day 0 to 90, 91 to 180, 181 to 270, and 271 to 360, respectively. The primary risk factors associated with CMV incidence were related to acute GVHD. PtCY was associated with a decreased risk of CMV infection. Letermovir prophylaxis did not associate with decreased CMV infection after Day + 90. In conclusion, the risk of CMV infection remains clinically significant until Day + 180, although this is affected by the GVHD status of the patient. Discontinuation of letermovir may be considered after Day + 180.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Infectious Diseases, Infection Control, and Employee Health, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Rohtesh S Mehta, Fareed Khawaja, Yosra Aljawai, Uday Popat
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Chen, G. L., Bassett, R., Mehta, R. S., Oran, B., Khawaja, F., Ariza-Heredia, E. J., Aljawai, Y., Olson, A., Daher, M., Smallbone, P., Rezvani, K., Kebriaei, P., Popat, U., Champlin, R., Chemaly, R. F., & Shpall, E. J. (2026). Late Cytomegalovirus Infections After Allogeneic Hematopoietic Cell Transplant. American Journal of Hematology. https://doi.org/10.1002/ajh.70347
Vancouver
Chen GL, Bassett R, Mehta RS, Oran B, Khawaja F, Ariza-Heredia EJ, et al. Late Cytomegalovirus Infections After Allogeneic Hematopoietic Cell Transplant. American Journal of Hematology. 2026. doi:10.1002/ajh.70347
BibTeX
@article{Chen2026,
author = {Chen, George L and Bassett, Roland and Mehta, Rohtesh S and Oran, Betul and Khawaja, Fareed and Ariza-Heredia, Ella J and Aljawai, Yosra and Olson, Amanda and Daher, May and Smallbone, Portia and Rezvani, Katayoun and Kebriaei, Partow and Popat, Uday and Champlin, Richard and Chemaly, Roy F and Shpall, Elizabeth J},
title = {Late Cytomegalovirus Infections After Allogeneic Hematopoietic Cell Transplant},
journal = {American Journal of Hematology},
year = {2026},
doi = {10.1002/ajh.70347}
}
EUVIMED